BioNTech SE annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioNTech SE Free Cash Flow (FCF) History (BNTX)
BioNTech SE reported €280.9M in free cash flow for fiscal 2025, an increase of €359.7M from the previous fiscal year, with a free cash flow margin of 9.79%.
View full BioNTech SE company overviewBioNTech SE free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | €280.9M | €359.7M | — | +9.79% |
| 2024 | 2024-12-31 | −€78.8M | −€5.20B | — | −2.86% |
| 2023 | 2023-12-31 | €5.12B | −€8.13B | −61.34% | +134.12% |
| 2022 | 2022-12-31 | €13.25B | €12.49B | +1638.15% | +76.53% |
| 2021 | 2021-12-31 | €762.2M | €841.7M | — | +4.02% |
| 2020 | 2020-12-31 | −€79.5M | €157.6M | — | −16.48% |
| 2019 | 2019-12-31 | −€237.1M | −€148.3M | — | −218.32% |
| 2018 | 2018-12-31 | −€88.8M | −€11.9M | — | −69.59% |
| 2017 | 2017-12-31 | −€76.9M | — | — | −124.81% |
BioNTech SE quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
BioNTech SE free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −€79.5M to €280.9M, a net increase of €360.4M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review BioNTech SE filings at SEC.gov ↗